In Vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 28483955)

Published in Antimicrob Agents Chemother on May 08, 2017

Authors

Elizabeth L Berkow1, David Angulo2, Shawn R Lockhart3

Author Affiliations

1: Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA kuu4@cdc.gov.
2: SCYNEXIS, Inc., Jersey City, New Jersey, USA.
3: Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Associated clinical trials:

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Candidiasis Caused by Candida Auris (CARES) (CARES) | NCT03363841